Session Abstract – PMWC 2026 Silicon Valley
"The PMWC 2026 AI for Clinical Decision Support Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
Confirmed Presenting Companies:
Speaker Profile
Ph.D., VP of Business Development, SeqOne
Biography
Michael Vishnevetsky is a seasoned commercial leader with extensive experience scaling companies in the genomics, diagnostics, and precision oncology space. Throughout his career, Michael has built high-impact strategic alliances and led commercial teams at industry-leading companies including Fabric Genomics, Personal Genome Diagnostics, and Invivoscribe. He brings a deep expertise in biopharma partnerships and companion diagnostics strategy, helping to connect innovative technologies with clinical and pharmaceutical partners.
Talk
Streamlining Precision Oncology: Flexible Pipelines for CGP Liquid Biopsy
This session introduces a next-generation, end-to-end bioinformatics solution for today's CGP and liquid biopsy labs. We demonstrate how this unified platform streamlines the entire analytical workflow, from raw FASTQ data to comprehensive report. We'll highlight the software's flexible architecture, which empowers labs to adapt to diverse assays, scale operations, and accelerate precision oncology.
AI for Clinical Decision Support Systems Showcase:
SeqOne
SeqOne is a leading European provider of AI-powered software for NGS data analysis in oncology and rare diseases. The cloud platform is HIPAA compliant and CE-IVD Class C certified. It transforms complex genomic data into fast, actionable insights, supporting molecular labs in delivering life-saving personalized treatments and scaling genomic medicine for every patient, everywhere.
Speaker Profile
CEO and Co-founder, PointHealth AI
Biography
Rachel Gollub is a serial entrepreneur and inventor, currently focused on precision medicine. Her goal is to bring rigor and precision to the prescription process. A Caltech graduate, she was on the team that wrote the Java language, then worked at Silicon Valley startups until she began to found her own. Her previous startup was acquired by UnitedHealth Group, where she worked as CTO of the EI space for several years before founding PointHealth AI.
Talk
PointHealth AI - Precision Treatments with Reinforcement Learning
PointHealth AI is providing clinicians with a decision support tool that uses reinforcement learning on millions of patients, along with integrated EHR data on the specific patient, to target the treatment that is most likely to work for a given patient in realtime, at the point of diagnosis.
AI for Clinical Decision Support Systems Showcase:
PointHealth AI
PointHealth AI was founded in 2024 in concert with the super{set} startup incubator, and brings precision medicine to clinicians across the world.
Speaker Profile
M.D., Ph.D., CMO, OpenEvidence
Biography
Dr. Travis Zack is Chief Physician at OpenEvidence and an adjunct professor at UCSF with a lab in predictive model development in real-world health data. His research lies at the intersection of computational biology, clinical medicine, and artificial intelligence. Travis received his PhD in Biophysics from Harvard and an MD in the Health Sciences and Technology track at MIT and Harvard Medical School. Dr. Zack has dedicated his career to using data-driven approaches to address pressing challenges in oncology. His lab focuses on developing AI models to support clinical decision-making and enhance patient outcomes, including machine learningbased tools for real-world evidence studies and natural language processing methods to extract valuable insights from electronic health records.
Talk
Award presentation
Award presentation
AI for Clinical Decision Support Systems Showcase:
OpenEvidence
Medical search platform
Speaker Profile
Ph.D., Assistant Professor, Vanderbilt U. Medical Ctr.
Biography
Cathy Shyr is an assistant professor of biomedical informatics, pediatrics, and biostatistics at Vanderbilt University Medical Center. She received her PhD in biostatistics from Harvard University and is a statistical informatician specializing in machine learning (ML), AI, and causal inference methods for estimating personalized treatment effects. Her research focuses on the development and implementation of novel statistical ML and AI methods to advance precision medicine. Dr. Shyr leads the AI initiatives at the Vanderbilt Undiagnosed Diseases Network, developing and implementing large language models that leverage electronic health records data to accelerate rare disease diagnosis. She has developed methods that improve the generalizability of statistical ML and causal inference models across multiple heterogeneous datasets for estimating personalized risks and treatment effects. She is an active member of the All of Us Research Programs Data and Research Center, where she leads the development of AI tools supporting the return of study results.
Talk
Accelerating Rare Disease Diagnosis with Artificial Intelligence
This showcase highlights AI and statistical machine learning methods developed using real-world rare disease patient data at the Vanderbilt Undiagnosed Diseases Network to improve diagnostic accuracy and efficiency. These tools provide a scalable, reproducible framework for accelerating diagnoses for health systems evaluating undiagnosed patients with complex and rare conditions.
AI for Clinical Decision Support Systems Showcase:
Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center and research institution known for its nationally recognized clinical programs, biomedical innovation, and translational science. VUMC integrates patient care, research, and education to advance precision medicine and improve health outcomes.
Speaker Profile
CEO, InSilicoTrials
Biography
Luca is a seasoned entrepreneur and expert in technology and healthcare, with a longstanding focus on advancing modeling and simulation within the life sciences sector. Prior to his current endeavors, he was the CEO of Emaze, a cybersecurity firm that specialized in automated security analysis for complex networks. He is actively involved in several advisory roles, including the Cloud Security Consultative Group at EMA, Co-chair of Avicenna Alliance's Good Simulation Practice (GSP) Task Force and member of the committee for the adoption of In Silico Medicine of the Italian Ministry of Health. He is also co-editor of the open-access book "Toward Good Simulation Practice: Best Practices for the Use of Computational Modeling Simulation in the Regulatory Process of Biomedical Products, published open access by Nature Springer in February 2024.
Talk
Transforming Clinical Trial Simulation with Causal GenAI
We explore how InSilicoTrials leverages Causal GenAI and advanced Digital Twin technologies to transform clinical trial simulation. Discover how AI-driven modeling accelerates study design, reduces risk, and enhances decision-making, enabling faster, smarter, and more efficient drug development.
AI for Clinical Decision Support Systems Showcase:
InSilicoTrials
We provide a cloud-based platform that uses in silico modeling, predictive AI, and synthetic patient simulations to generate robust, regulatory-grade digital evidence; accelerating the go-to-market timeline and extending market exclusivity up to 4 years.
